Stock Events

Stock Events

Biomind Labs 

$0.2502
3
-$0.21-45.61%Wednesday 17:34

Statistics

Day High
0.2502
Day Low
0.2502
52W High
0.8
52W Low
0.011
Volume
1,000
Avg. Volume
1,053
Mkt Cap
19.41M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Dividends

0%Dividend Yield
Nov 2020
$0.37
Dec 2019
$2.48
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-850,000Net Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Compass Pathways
CMPS
Mkt Cap1.6B
Compass Pathways operates in the psychedelic medicine sector, focusing on psilocybin therapy for depression, similar to Biomind's work on psychedelic-based treatments.
AtaiBeckley
ATAI
Mkt Cap2.73B
ATAI Life Sciences is a biotech company researching and developing treatments using psychedelics, overlapping with Biomind Labs' focus areas.
GH Research
GHRS
Mkt Cap1.43B
GH Research focuses on developing 5-MeO-DMT therapies for depression, a direct competitor in the psychedelic treatment market.
Revive Therapeutics
RVVTF
Mkt Cap9.15M
Revive Therapeutics explores psychedelic medicines for various disorders, positioning it as a competitor in the psychedelic drug development industry.
Nuveen Municipal Income
NUMI
Mkt Cap0
Numinus Wellness focuses on psychedelic production and therapy, similar to Biomind Labs' objectives in mental health treatment innovations.
Noveris Health Sciences
MYCOF
Mkt Cap42.74M
Mydecine Innovations Group works on developing and commercializing psychedelic medicines, competing in the same therapeutic space as Biomind Labs.

About

Biomind Labs Inc., a biotech research and development company, focuses on developing novel pharmaceutical drugs and nanotech delivery systems for various psychiatric and neurological conditions. The company is developing BMND01, which is in Phase II clinical trials for use in the treatment of depression; BMND08, a 5-Metoxi-N,N-dimethyltryptamine based formulation that is in Phase II clinical trials for treatment of depression and anxiety in patients with Alzheimer's-type cognitive impairment; BMND06 is in Phase I clinical trial for treatment of morbid obesity; and BMDO9 is in Phase I clinical trial for treatment of Parkinson's disease. It is also developing preclinical drug candidates, including BMND02 for the treatment of fibromyalgia, BMND03 for the treatment of addictive disorders, BMND05 for the treatment of chronic pain, BMND05 for the treatment of inflammatory disorders, and BMND07 for the treatment of major depressive disorder. The company is headquartered in Canelones, Uruguay.
Show More
CEO
Mr. Alejandro Antalich
Employees
5
Country
Germany
ISIN
CA0907021012
WKN
000A3CSQR

Listings

CN
CA
BMND.CN
NEO
CA
BMND.NEO
OTC Link
US
BMNDF
F
DE
3XI.F

0 Comments

Share your thoughts

FAQs

What is Biomind Labs stock price today?▼
The current price of BMNDF is $0.25 USD — it has decreased by -45.61% in the past 24 hours. Watch Biomind Labs stock price performance more closely on the chart.
What is Biomind Labs stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Biomind Labs stocks are traded under the ticker BMNDF.
Is Biomind Labs stock price growing?▼
BMNDF stock has risen by +0% compared to the previous week, the month change is a -45.61% fall, over the last year Biomind Labs has showed a +1,483.54% increase.
What is Biomind Labs market cap?▼
Today Biomind Labs has the market capitalization of 19.41M
What is Biomind Labs revenue for the last year?▼
Biomind Labs revenue for the last year amounts to 0 USD.
What is Biomind Labs net income for the last year?▼
BMNDF net income for the last year is -850,000 USD.
Does Biomind Labs pay dividends?▼
Yes, BMNDF dividends are paid annual. The last dividend per share was 0.37 . As of today, Dividend Yield (FWD)% is 0%.
How many employees does Biomind Labs have?▼
As of November 4, 2026, the company has 5 employees.
In which sector is Biomind Labs located?▼
Biomind Labs operates in the Health & Wellness sector.
When did Biomind Labs complete a stock split?▼
The last stock split for Biomind Labs was on July 30, 2021 with a ratio of 1:32.5.
Where is Biomind Labs headquartered?▼
Biomind Labs is headquartered in Canelones, Germany.